Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Women's health
Biotech
ObsEva sells off one of 2 remaining assets to stay afloat
Only two months after cutting staff by 70% to focus much of its remaining resources on preterm labor treatment ebopiprant, ObsEva is now selling it.
James Waldron
Nov 22, 2022 7:35am
FDA, Edwards on how devicemakers can better serve women
Oct 26, 2022 2:12pm
Astellas' menopause therapy accepted for FDA review
Aug 18, 2022 8:50am
Hologic caps off year of European expansion with new French HQ
Mar 24, 2022 1:05pm
Astellas gets safety win for menopause in late-stage trial
Mar 7, 2022 10:12am
With approval in sight, ObsEva offloads women's health drug
Feb 11, 2022 4:54am